tiprankstipranks
Advertisement
Advertisement
Arcutis Biotherapeutics Earnings Call Highlights Growth Momentum
PremiumCompany AnnouncementsArcutis Biotherapeutics Earnings Call Highlights Growth Momentum
25d ago
Arcutis Biotherapeutics price target raised to $38 from $34 at Morgan Stanley
Premium
The Fly
Arcutis Biotherapeutics price target raised to $38 from $34 at Morgan Stanley
1M ago
Arcutis Biotherapeutics price target raised to $36 from $35 at Mizuho
Premium
The Fly
Arcutis Biotherapeutics price target raised to $36 from $35 at Mizuho
1M ago
Arcutis Biotherapeutics raises FY26 revenue view to $525M-$540M from $480M-$495M
PremiumThe FlyArcutis Biotherapeutics raises FY26 revenue view to $525M-$540M from $480M-$495M
1M ago
Arcutis Biotherapeutics Adds Veteran Director to Board
Premium
Company Announcements
Arcutis Biotherapeutics Adds Veteran Director to Board
2M ago
Arcutis appoints Mirum Pharmaceuticals CEO Christopher Peetz to board
Premium
The Fly
Arcutis appoints Mirum Pharmaceuticals CEO Christopher Peetz to board
2M ago
Arcutis Earnings Call Signals Momentum Amid Headwinds
PremiumCompany AnnouncementsArcutis Earnings Call Signals Momentum Amid Headwinds
4M ago
Arcutis Biotherapeutics price target lowered to $34 from $35 at Morgan Stanley
Premium
The Fly
Arcutis Biotherapeutics price target lowered to $34 from $35 at Morgan Stanley
4M ago
Arcutis Biotherapeutics: Buy Rating Reaffirmed as Zoryve Momentum Supports Growth Outlook; $35 Price Target Maintained
Premium
Ratings
Arcutis Biotherapeutics: Buy Rating Reaffirmed as Zoryve Momentum Supports Growth Outlook; $35 Price Target Maintained
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100